Fig. 6

Human alveolar basal cells form HC-like structures in bleomycin-challenged mouse lungs. NRG mice were treated with bleomycin (n = 3), or bleomycin + human alveolar BC carrying a luciferase encoding vector (n = 3), or bleomycin + human alveolar BC (n = 3) as illustrated (A). Luciferase expression in mice treated with bleomycin or bleomycin + human alveolar BC carrying a luciferase encoding vector (B) and the corresponding bioluminescence measurements (C) at day 1, 8, and 15. Representative images of H&E stainings in mice treated with bleomycin or bleomycin + human alveolar BC (D). Representative IHC image of TTF-1 in mice treated with bleomycin + human alveolar BC (E). Representative IHC/IF images of mouse lung tissue (mice treated with bleomycin + human alveolar BC) incubated with antibodies detecting human-specific HNA with or without SCGB1A1, MUC5AC, MUC5B, KRT17, KRT5, or AcTub. Nuclei were counter-stained with DAPI. White squares (1, and 2) indicate regions imaged at higher magnification (F)